Full Press Release Details
Charles H. Sherwood, Ph.D., CEO
Kevin W. Quinlan, CFO
ANIKA THERAPEUTICS APPOINTS LIFE SCIENCES VETERAN
RAYMOND J. LAND TO BOARD OF DIRECTORS
Woburn, Mass. January 25, 2006 Anika Therapeutics, Inc. (Nasdaq:
ANIK) today announced that it has appointed Raymond J. Land as a new independent
director on the company s board. Land
will become the chairperson of the board s audit committee. He has more than 30 years of experience in
senior finance roles, the past 16 in the life sciences industry. Today the company also announced that Samuel F.
McKay has resigned from the company s board to devote more time to other
business and personal commitments.
Ray is a seasoned financial executive with significant experience at
publicly held life sciences companies, said Joseph L. Bower, Donald Kirk
David Professor of Business Administration, Harvard Business School, Anika s
lead director. He has been successful
in overseeing corporate growth, developing and executing strategic plans, and completing
major financial transactions. His industry
experience and financial acumen will be valuable assets to the board.
Last year, Land joined Orchid Cellmark, a publicly traded provider of
identity DNA testing services, as chief financial officer. For eight years, Land was senior vice
president and chief financial officer of Genencor International, where he completed
an IPO and oversaw significant sales and income growth. Land also served for five years as senior vice
president and chief financial officer of West Pharmaceutical Services, and for
nine years in financial management positions at Campbell Soup Company. Land is a certified public accountant and
holds a BA from Temple University, Ambler, in accounting/finance. He also serves on the board of Mountain View
I would like to thank Sam for his 10 years of dedication to Anika,
continued Bower. We valued his guidance
on the board and wish him well in his future endeavors. McKay is a general partner of Axiom Venture
Partners Limited Partnership and the chief executive officer of Axiom Venture
Working with Anika and the Anika Board over the past ten years has
been extremely gratifying said McKay. McKay led Anika s 1995 venture financing and
joined the board at that time. It is
typical for venture investors to leave a public company board after their work
is done and after their Partnership s investment cycle is completed. I feel
good about doing so at this point in time and when there is someone of Ray Land s
high caliber joining the board . McKay continued.
About Anika Therapeutics, Inc.
Headquartered in Woburn, Mass., Anika Therapeutics, Inc.
(www.anikatherapeutics.com) develops, manufactures and commercializes
therapeutic products and devices intended to promote the repair, protection and
healing of bone, cartilage and soft tissue.
These products are based on hyaluronic acid (HA), a naturally occurring,
biocompatible polymer found throughout the body. Anika products include OrthoVisc ,
a treatment for osteoarthritis of the knee available internationally and
marketed in the U.S. by DePuy Mitek and Ortho Biotech Products, L.P., and
Hyvisc , a treatment for equine osteoarthritis marketed in the U.S.
by Boehringer Ingelheim Vetmedica, Inc.
Anika manufactures Amvisc and Amvisc Plus , HA viscoelastic products
for ophthalmic surgery. It also produces
STAARVISC -II, which is distributed by STAAR Surgical Company and Shellgel for
Cytosol Ophthalmics, Inc.